Literature DB >> 2656909

Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (avidity-ELISA) and by haemolysis typing.

K Hedman1, J Hietala, A Tiilikainen, A L Hartikainen-Sorri, K Räihä, J Suni, P Väänänen, M Pietiläinen.   

Abstract

Two tests were introduced recently for assessment of the avidity of rubella immunoglobulin antibodies. In the quantitative test--avidity-enzyme linked immunosorbent assay (ELISA)--IgG antibodies obtained from individuals shortly after primary infection with rubella virus are distinguished from those with past immunity by their antigen-elution characteristics. This method uses agents that disrupt hydrophobic bonds in proteins [Kamoun PP (1988): Denaturation of globular proteins by urea: Breakdown of hydrophobic bonds? Trends in Biological Sciences 13:424-425.]. In the semiquantitative, presumptive test--haemolysis typing--the low-avidity rubella-IgG antibodies are distinguished from the high-avidity antibodies by the quality of their haemolytic zones in a radial haemolysis test. In the present study, both tests were applied to sera taken before and after vaccination with two different strains (Cendehill or RA 27/3) of live attenuated rubella virus. It was found that after vaccination of previously nonimmune subjects, IgG synthesized during the first 2 months had a very low avidity; IgG avidity increased dramatically during the subsequent 4 months and less markedly between 6 and 12 months after vaccination. On the contrary, the initially high IgG avidity of previous immune vaccinees remained at an elevated level postvaccination. These results provide a basis for identification of recent primary rubella virus infections, or vaccination reactions, by the avidity of specific IgG and also for their separation from rubella reinfections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2656909     DOI: 10.1002/jmv.1890270407

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

1.  Analysis of the antibody response to an immunodominant epitope of the envelope glycoprotein of a lentivirus and its diagnostic potential.

Authors:  Franca Mordasini; Hans-Rudolf Vogt; Marie-Luise Zahno; Ariane Maeschli; Chiara Nenci; Reto Zanoni; Ernst Peterhans; Giuseppe Bertoni
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

2.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.

Authors:  K S Cole; M Murphey-Corb; O Narayan; S V Joag; G M Shaw; R C Montelaro
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.

Authors:  S A Hammond; S J Cook; D L Lichtenstein; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus.

Authors:  Anne-Marie Roque-Afonso; Liliane Grangeot-Keros; Bénédicte Roquebert; Delphine Desbois; Jean-Dominique Poveda; Vincent Mackiewicz; Elisabeth Dussaix
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

6.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Authors:  Karen K Yam; Jyotsana Gupta; Angela Brewer; David W Scheifele; Scott Halperin; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

8.  Avidity of Aspergillus umbrosus IgG antibodies in farmer's lung disease.

Authors:  K Kaukonen; J Savolainen; M Viander; E O Terho
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

9.  Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus.

Authors:  Yanli Zeng; Yiqiang Lin; Xuelian Wang; Yan Zhang; Feng Peng; JiaJia Wang; Longcan Jiang; Shiqiong Liang; Yun Xiao
Journal:  Clin Rheumatol       Date:  2020-03-18       Impact factor: 2.980

10.  Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis.

Authors:  Lenka Fialová; Ales Bartos; Jana Svarcová; Ivan Malbohan
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.